Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of ...

attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC ...